cadonilimab   Click here for help

GtoPdb Ligand ID: 12966

Synonyms: AK-104 | AK104
Approved drug Immunopharmacology Ligand
cadonilimab is an approved drug (China NMPA (2022))
Compound class: Antibody
Comment: Cadonilimab (AK104) is a humanized, bispecific monoclonal antibody that simultaneously targets the immune checkpoint proteins PD-1 and CTLA-4. It was designed as a cancer immunotherapy (immuno-oncology) agent.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
References
1. Frentzas S, Gan HK, Cosman R, Coward J, Tran B, Millward M, Zhou Y, Wang W, Xia D, Wang ZM et al.. (2023)
A phase 1a/1b first-in-human study (COMPASSION-01) evaluating cadonilimab in patients with advanced solid tumors.
Cell Reports Medicine, Epub ahead of print. DOI: https://doi.org/10.1016/j.xcrm.2023.101242
2. Pang X, Huang Z, Zhong T, Zhang P, Wang ZM, Xia M, Li B. (2023)
Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity.
MAbs, 15 (1): 2180794. [PMID:36872527]
3. Zhao Y, Ma Y, Fan Y, Zhou J, Yang N, Yu Q, Zhuang W, Song W, Wang ZM, Li B et al.. (2023)
A multicenter, open-label phase Ib/II study of cadonilimab (anti PD-1 and CTLA-4 bispecific antibody) monotherapy in previously treated advanced non-small-cell lung cancer (AK104-202 study).
Lung Cancer, 184: 107355. [PMID:37677918]